ID   K562/NIL-50
AC   CVCL_4V51
DR   Wikidata; Q54899416
RX   PubMed=22712605;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Tasigna).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 14
//
RX   PubMed=22712605; DOI=10.7785/tcrt.2012.500281;
RA   Ceylan C., Camgoz A., Baran Y.;
RT   "Macromolecular changes in nilotinib resistant K562 cells; an in vitro
RT   study by Fourier transform infrared spectroscopy.";
RL   Technol. Cancer Res. Treat. 11:333-344(2012).
//